Xifaxan and Liver disease
Result of checking the interaction of drug Xifaxan and disease Liver disease for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:Rifaximin is metabolized by the liver. Following administration of rifaximin 550 mg twice daily to patients with a history of hepatic encephalopathy, systemic exposure (AUC) was about 10-, 13- and 20- fold higher in patients with mild (Child-Pugh A), moderate (Child-Pugh B) and severe (Child-Pugh C) hepatic impairment, respectively, compared to that in healthy volunteers. Animal toxicity studies did not achieve systemic exposures that were seen in patients with severe hepatic impairment, thus clinical significance is unknown. No dosage adjustment is recommended because systemic absorption of rifaximin is presumably limited. Nonetheless, therapy with rifaximin should be administered cautiously in patients with severe hepatic impairment.